# Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.

> **NCT01933568** · PHASE1 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 15 (actual)

## Conditions studied

- Inoperable Locally Advanced Non Small Cell Lung Cancer

## Interventions

- **RADIATION:** SABR
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01933568
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-28
- **Primary completion:** 2018-11-11
- **Final completion:** 2018-11-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933568, "Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01933568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*